White paper
Turning EHR-connected clinical intelligence into coordinated, measurable action across the full product lifecycle: for Medical Affairs, HEOR, Government Affairs, Thought Leader Liaisons, Commercial, and Marketing.
Free download, no form. Last reviewed:
Who it's for
The paper is aimed at pharmaceutical leaders in complex, specialty, and rare disease markets, where patient journeys are fragmented and diagnosed-but-untreated populations are often substantial. It speaks to six functions in particular:
What's inside
1
Most pharmaceutical teams already have access to plenty of data. The paper argues the gap is turning clinical intelligence into coordinated action across the six functions above, instead of each team working from its own proxies and lagging reports.
2
A Reuters Insights and Scale AI study of nearly 500 senior AI decision makers found that only 6.5% had integrated AI across the business, moved most pilots into production, and stayed ahead of plan. The paper maps those behaviors to a clinical intelligence program.
3
The same intelligence layer supports pre-launch work (prevalence refinement, care-gap mapping, sizing diagnosed-but-untreated populations), launch execution, and post-launch growth, so functions reinforce one another instead of reconciling competing assumptions.
4
Care-gap maps and real-world research opportunities for Medical Affairs, refined burden estimates for HEOR, care-inequity analysis for Government Affairs, expert mapping for TLLs, and specialty-level insight for Commercial and Marketing.
5
A phased implementation path: start with one brand or disease area, establish executive sponsorship, cross-functional governance, and compliant data use up front, and measure against agreed KPIs such as diagnosed-but-untreated ratio and clinician access.
Reported results
The paper includes headline outcomes observed across PathfindEHR™ implementations in more than 150 health systems and 80 independent practices.
2:1
patients identified for every one on therapy
4:1
diagnosed-but-untreated patient ratio
+70%
increase in clinician access
Sponsor-provided implementation results, pending independent external validation. The paper discusses these figures and their caveats in full.
Ten pages, free, no form. If it raises questions about your disease area, we're glad to talk them through.
